AI and the Pharmaceutical Industry — 2026-10-15 (Thu)

Overview

Today's pharma-AI coverage centers on individual drug discovery partnerships and financings, and no single deal stands out. The most eye-catching figure is the Zealand Pharma and Generate Biomedicines collaboration (up to $1.2 billion, not a committed amount). The FDA's $49 Million IDIQ contract with ThinkTrends is different in kind, as it reflects AI implementation spending on the regulator's side. Moves to put infrastructure into research settings are also visible, such as the partnership between Waters and Anthropic.

By Category

In drug discovery, Rakovina Therapeutics is financing AI-driven cancer drug discovery through a C$1.99 Million private placement. Deep Origin and BioAge Labs are reported to have validated hits against the first target in their multi-target collaboration. The capital tie-up between ITOCHU and MOLCURE brings a trading company in as an investor in AI drug discovery in Japan.

In clinical development, Cori Clinical raised US$4m, which it will use to expand its AI platform for clinical trial design. The amount is small, but money is starting to flow into stages further downstream than drug discovery.

In Medical Affairs, Johns Hopkins Medicine has partnered with OpenEvidence on medical education and clinical care. No financial terms were disclosed.

In enterprise AI infrastructure and governance, the Waters and Anthropic partnership targets autonomous lab workflows. AIM Media House's commentary that "technological progress has outpaced adoption" suggests that on-the-ground uptake is lagging behind the pace of investment. As a market forecast, there are reports that IQVIA, Oracle, Accenture, Veeva Systems and SAP are targeting $82.24B (planned/projected) in the Global Life Sciences IT market.

Reading the Investment Map

The committed amounts are Rakovina's C$1.99 Million, Cori Clinical's US$4m, and ThinkTrends' $49 Million (the FDA's IDIQ contract). An IDIQ is a framework contract. It is the largest of these, but as public-sector procurement it should be read as a separate stream from private drug discovery investment. The Zealand Pharma and Generate collaboration carries a ceiling of $1.2 billion, which is not a committed amount. Nanyang Biologics' US$1.5 billion is reported as a figure akin to a valuation, and the company is at the stage of awaiting a Nasdaq listing. The Life Sciences IT market's $82.24B is a plan or projection, not an actual result. The statement that Nubeen Asset Management holds $2.6 trillion in assets under management refers to its AUM and is not an amount invested in pharma AI. Funding is spread across drug discovery partnerships and licensing, clinical trial design, and support for public-sector data and AI implementation.

What to Watch

Follow-up news on Nanyang Biologics' Nasdaq listing (timing, terms). 2. Whether the committed portions of the Zealand Pharma and Generate collaboration, such as the upfront payment, will be disclosed.